



## Immunomodulators Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Medication requested

##### Anti-TNFs

- Cimzia (certolizumab)
- Enbrel (etanercept)
- Humira (adalimumab)
- Inflectra (infliximab-dyyb)
- Remicade (infliximab)
- Renflexis (infliximab-abda)
- Simponi (golimumab)
- Simponi Aria (golimumab for infusion)

##### Interleukin Antagonists

- Actemra (tocilizumab)
- Cosentyx (secukinumab)
- Ilumya (tildrakizumab-asmn)
- Kevzara (sarilumab)
- Kineret (anakinra)
- Siliq (brodalumab)
- Skyrizi (risankizumab-rzaa)
- Stelara (ustekinumab)
- Taltz (ixekizumab)
- Tremfya (guselkumab)

##### Miscellaneous Agents

- Entyvio (vedolizumab)
- Olumiant (baricitinib)
- Orencia (abatacept)
- Otezla (apremilast)
- Rinvoq (upadacitinib)
- Xeljanz (tofacitinib)
- Xeljanz XR (tofacitinib extended-release)

#### Dose, frequency, and duration of medication requested \_\_\_\_\_

#### Indication (Check all that apply.)

- |  |  |  |
|--|--|--|
| <input type="checkbox"/> Ankylosing spondylitis (AS)<br><input type="checkbox"/> Axial (spine) involvement | <input type="checkbox"/> Juvenile idiopathic arthritis (JIA)<br><input type="checkbox"/> Polyarticular <input type="checkbox"/> Systemic | <input type="checkbox"/> Oral ulcers associated with Behcet's disease                                    |
| <input type="checkbox"/> Crohn's disease   | <input type="checkbox"/> Neonatal-onset multisystem inflammatory disease (NOMID)   | <input type="checkbox"/> Plaque psoriasis (PsO)  |
| <input type="checkbox"/> Cytokine release syndrome   | <input type="checkbox"/> Non-infectious uveitis  | <input type="checkbox"/> Psoriatic arthritis (PsA)<br><input type="checkbox"/> Axial (spine) involvement |
| <input type="checkbox"/> Giant cell arteritis (GCA)  | <input type="checkbox"/> Non-radiographic axial spondyloarthritis (nr-AxSpA)   | <input type="checkbox"/> Rheumatoid arthritis (RA)   |
| <input type="checkbox"/> Hidradenitis suppurativa (HS) (Hurley Stage II or III)                            |  | <input type="checkbox"/> Ulcerative colitis (UC)   |
|  |  | <input type="checkbox"/> Other _____   |

Please specify severity of indication below.

- Mild       Mild-moderate       Moderate       Moderate-severe       Severe

#### Please complete the following for all requests.

1. Member's current weight \_\_\_\_\_

2. Please indicate billing preference.  Pharmacy  Prescriber in-office  Hospital outpatient  
For hospital outpatient billing, provide department-specific facility NPI. \_\_\_\_\_  
Drug NDC (if known) or service code \_\_\_\_\_
3. Is the member stabilized on the requested medication?  Yes. Please provide start date. \_\_\_\_\_  No
- 

**Section I. Please complete for all requests, except for a diagnosis of cytokine release syndrome, GCA, HS (Hurley Stage II or III), NOMID, non-infectious uveitis, nr-AxSpA, or oral ulcers associated with Behcet's disease.**

Has the member tried traditional or biologic disease modifying antirheumatic drugs (DMARDs)?

- Yes. Please list the drug names, dates/duration of trials and outcomes in Section VIII below.\*  
 No. Please explain why not. \_\_\_\_\_
- 

**Section II. Please also complete for treatment of PsO with Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Inflectra, Otezla, Remicade, Renflexis, Siliq, Skyrizi, Stelara, Taltz, or Tremfya.**

Has the member tried other therapies to treat this condition including topical agents, systemic agents, and phototherapy?

- Yes. Please list the names of the therapies, dates/duration of trials and outcomes in Section VIII below.\*  
 No. Please explain why not. \_\_\_\_\_
- 

**Section III. Please also complete for treatment of Crohn's disease with Cimzia, Entyvio, Humira, Inflectra, Remicade, Renflexis, or Stelara.**

1. Has the member tried other medications to treat this condition including aminosalicylate, antibiotic, corticosteroid, and an immunomodulator (e.g., azathioprine, 6-mercaptopurine, or methotrexate)?

- Yes. Please list the drug names, dates/duration of trials and outcomes in Section VIII below.\*  
 No. Please explain why not. \_\_\_\_\_
2. If the request is for Inflectra, Remicade, or Renflexis, does the member have fistulizing Crohn's disease?  
 Yes  No
- 

**Section IV. Please also complete for treatment of UC with Entyvio, Humira, Inflectra, Remicade, Renflexis, Simponi, Stelara, or Xeljanz.**

Has the member tried other medications to treat this condition including aminosalicylate, corticosteroid, and an immunomodulator (e.g., azathioprine or 6-mercaptopurine)?

- Yes. Please list the drug name, dates/duration of trials and outcomes in Section VIII below.\*  
 No. Please explain why not. \_\_\_\_\_
- 

**Section V. Please also complete for treatment of AS with anti-TNFs, Cosentyx, and Taltz. Please complete for treatment of nr-AxSpA with Cimzia.**

Has the member tried two nonsteroidal anti-inflammatory drugs (NSAIDs)?

- Yes. Please list the drug names, dates/duration of trials and outcomes in Section VIII below.\*  
 No. Please explain why not. \_\_\_\_\_
- 

**Section VI. Please complete for treatment of non-infectious uveitis with Humira and for treatment of GCA with Actemra.**

Has the member tried other medications to treat this condition including glucocorticoid and immunosuppressive therapy?

- Yes. Please list the drug name, dates/duration of trials and outcomes in Section VIII below.\*

No. Please explain why not. \_\_\_\_\_

---

**Section VII. Please complete for treatment of cytokine release syndrome with Actemra IV.**

Please provide anticipated date of administration with concurrent CAR T-cell therapy. \_\_\_\_\_

---

**Section VIII. Please complete for all requests as needed.**

Please provide the following information regarding previous trials.\*

Drug name/Therapy \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

\_\_\_\_\_  
Drug name/Therapy \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

\_\_\_\_\_  
Drug name/Therapy \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

\_\_\_\_\_  
Drug name/Therapy \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

\_\_\_\_\_  
Drug name/Therapy \_\_\_\_\_ Dates/duration of use \_\_\_\_\_

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

---

**Section IX. Please complete for requests for quantities above quantity limits.**

Please describe the clinical rationale for exceeding the quantity limit.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

---

**Section X. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

\_\_\_\_\_  
\_\_\_\_\_

\* Please attach a letter documenting additional trials as necessary.

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

*\* Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_